Coastline Trust Co Has $496,000 Stock Position in Bristol-Myers Squibb (NYSE:BMY)

Coastline Trust Co raised its position in Bristol-Myers Squibb (NYSE:BMY) by 23.6% during the third quarter, Holdings Channel.com reports. The institutional investor owned 9,592 shares of the biopharmaceutical company’s stock after purchasing an additional 1,830 shares during the quarter. Coastline Trust Co’s holdings in Bristol-Myers Squibb were worth $496,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in BMY. First Foundation Advisors increased its stake in shares of Bristol-Myers Squibb by 20.1% in the first quarter. First Foundation Advisors now owns 3,270 shares of the biopharmaceutical company’s stock valued at $177,000 after buying an additional 548 shares in the last quarter. Acadian Asset Management LLC increased its position in Bristol-Myers Squibb by 76.1% in the 1st quarter. Acadian Asset Management LLC now owns 620,324 shares of the biopharmaceutical company’s stock valued at $33,632,000 after acquiring an additional 268,006 shares in the last quarter. Catalytic Wealth RIA LLC lifted its position in shares of Bristol-Myers Squibb by 33.1% during the first quarter. Catalytic Wealth RIA LLC now owns 9,086 shares of the biopharmaceutical company’s stock worth $493,000 after purchasing an additional 2,258 shares in the last quarter. Covestor Ltd grew its stake in shares of Bristol-Myers Squibb by 22.4% during the first quarter. Covestor Ltd now owns 5,558 shares of the biopharmaceutical company’s stock valued at $302,000 after purchasing an additional 1,019 shares during the last quarter. Finally, Bahl & Gaynor Inc. increased its holdings in shares of Bristol-Myers Squibb by 2.7% in the first quarter. Bahl & Gaynor Inc. now owns 44,568 shares of the biopharmaceutical company’s stock valued at $2,417,000 after purchasing an additional 1,183 shares in the last quarter. 76.41% of the stock is owned by institutional investors.

Insider Transactions at Bristol-Myers Squibb

In other Bristol-Myers Squibb news, EVP Samit Hirawat acquired 1,830 shares of the business’s stock in a transaction dated Friday, November 1st. The stock was bought at an average cost of $54.67 per share, with a total value of $100,046.10. Following the completion of the transaction, the executive vice president now directly owns 62,109 shares in the company, valued at approximately $3,395,499.03. This represents a 3.04 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, SVP Phil M. Holzer sold 700 shares of the company’s stock in a transaction on Monday, November 4th. The shares were sold at an average price of $55.62, for a total transaction of $38,934.00. Following the completion of the transaction, the senior vice president now owns 11,760 shares in the company, valued at approximately $654,091.20. This represents a 5.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 0.09% of the company’s stock.

Bristol-Myers Squibb Price Performance

NYSE BMY opened at $56.22 on Friday. The company has a debt-to-equity ratio of 2.83, a quick ratio of 1.09 and a current ratio of 1.24. Bristol-Myers Squibb has a 52-week low of $39.35 and a 52-week high of $61.08. The business has a 50 day simple moving average of $52.73 and a 200 day simple moving average of $47.25. The stock has a market cap of $114.02 billion, a price-to-earnings ratio of -15.66, a PEG ratio of 15.83 and a beta of 0.44.

Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported $1.80 EPS for the quarter, beating the consensus estimate of $1.49 by $0.31. The business had revenue of $11.89 billion for the quarter, compared to analysts’ expectations of $11.26 billion. Bristol-Myers Squibb had a negative net margin of 15.30% and a positive return on equity of 11.94%. The firm’s revenue was up 8.4% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.00 EPS. Analysts anticipate that Bristol-Myers Squibb will post 0.92 earnings per share for the current fiscal year.

Bristol-Myers Squibb Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, November 1st. Shareholders of record on Friday, October 4th were paid a $0.60 dividend. This represents a $2.40 annualized dividend and a yield of 4.27%. The ex-dividend date was Friday, October 4th. Bristol-Myers Squibb’s payout ratio is -66.85%.

Analysts Set New Price Targets

Several equities research analysts have recently commented on the company. Sanford C. Bernstein assumed coverage on Bristol-Myers Squibb in a research note on Thursday, October 17th. They issued a “market perform” rating and a $56.00 target price for the company. Jefferies Financial Group boosted their price objective on Bristol-Myers Squibb from $49.00 to $51.00 and gave the stock a “hold” rating in a report on Wednesday, August 28th. Daiwa America raised shares of Bristol-Myers Squibb from a “hold” rating to a “strong-buy” rating in a research note on Wednesday. BMO Capital Markets boosted their price target on shares of Bristol-Myers Squibb from $57.00 to $61.00 and gave the stock a “market perform” rating in a research note on Tuesday, November 12th. Finally, Barclays raised their price objective on shares of Bristol-Myers Squibb from $42.00 to $43.00 and gave the company an “underweight” rating in a research note on Monday, October 7th. Two research analysts have rated the stock with a sell rating, fourteen have given a hold rating, two have issued a buy rating and three have given a strong buy rating to the company’s stock. According to MarketBeat, Bristol-Myers Squibb currently has a consensus rating of “Hold” and an average target price of $54.07.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.